Insulin Degludec
Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.
Insulin Degludec (brand name Tresiba) — Antidiabetic; Ultra-long-acting basal insulin analog.
Identification
- Therapeutic class: Antidiabetic.
- Pharmacologic class: Ultra-long-acting basal insulin analog.
Pharmacology
- Mechanism of action: Basal replacement with very flat, prolonged action.
- Onset / peak / duration: Onset about 1 hour; duration over 42 hours.
- Half-life / therapeutic level: About 25 hours; monitor glucose.
Clinical use
- Indications: Type 1 and type 2 diabetes.
- Usual dose, route, frequency: SubQ once daily, flexible timing.
- Maximum dose / adjustments: Individualized.
Safety
- Contraindications: Hypoglycemia, hypersensitivity.
- Black box warning: None.
- Interactions: Same insulin interactions.
- Pregnancy / lactation: Insulin preferred.
- High-alert: Yes.
Adverse effects
- Common side effects: Hypoglycemia, injection reactions.
- Serious effects to report: Severe hypoglycemia.
- Antidote / reversal: Glucose or glucagon.
Nursing process
- Assessment before administration: Blood glucose.
- Interventions during therapy: Do not mix; rotate sites.
- Monitor: Blood glucose, A1c.
- Evaluation / expected outcome: Stable basal control.
Patient teaching
- Patient teaching: Long duration allows flexible timing but be consistent.
- Notify provider if: Frequent lows or highs.
- Administration tips: SubQ; rotate sites.